Google
HELP — CYBIN INC. COMMON STOCK (Healthcare >> Biotechnology)
HELP FAQ
What is HELP's ROE?
CYBIN INC. COMMON STOCK reports a Return on Equity (ROE) of -52.92%.
What is HELP's dividend yield?
CYBIN INC. COMMON STOCK offers a dividend yield of 0.00%.
What is HELP's Deepscope Quality Score?
Deepscope rates HELP's overall financial quality at 8 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy HELP?
Deepscope's AI Timing Score for HELP is 26 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does HELP belong to?
CYBIN INC. COMMON STOCK is classified under the Healthcare >> Biotechnology sector on the NYSE MKT exchange.
|
USD 4.15
Price
-0.28
(-6.32%)
Day Change
|
|
|---|
HELP, ファンダメンタルスコアはnot good ( ファンダメンタル = 8) そして テクニカルスコアは ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROEが低い
ROAが低い
ROEの伸びが低い
平均ROEが低い
昨年度のROEが一昨年比で低い
ROEが昨年度比で低い
ROAがROEに比べて低い
ROAの伸びが低い
Last-year ROA is lower than last-2-years ROA.
昨年度のROAが一昨年比で低い
NPMが低い
NPMの伸びが低い
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
In details, quality factors are not good , financial health is not good , and ability to make profit is not good , ...
| Deepscope 分析 |
|
48% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 84 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 4.15 |
| PBV / Sector |
0.78 / 4.63
GREAT
|
| Earning Per Share | -2.80 |
| PE / Sector |
N/A / 17.43
|
| PEG or PE/Growth / Sector |
N/A / 0.53
|
| Average 1M Daily Value |
2.98 M
GREAT
|
| Average 1W Daily Value |
2.86 M
GREAT
|
| Timing Factors |
|
14% |
| Financial Health |
|
45% |
| ポイントになる統計 |
|
37% |
| 配当 |
|
4% |
| 登録情報 |
| Analyze Date | 2026-06-06 09:08:45 |
| Symbol | HELP |
| Name | CYBIN INC. COMMON STOCK |
| Sector | Healthcare >> Biotechnology |
| Market | NYSE MKT |
| Listed Shares | 49.89 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 214.54 / 8,857.28 |
| ニュース |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 100 King Street West, Toronto, ON, Canada, M5X 1C9
Phone: 908-764-8385
Website: https://cybin.com
Sector: Healthcare >> Biotechnology
Description: Cybin Inc., doing business as Helus Pharma, a clinical-stage neuropsychiatry company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions. It develops CYB003, a deuterated psilocybin analog, which is in phase 3 clinical trial to treat major depressive disorder (MDD); and CYB004, a deuterated N, N-dimethyltryptamine (DMT), which is in phase 2 clinical trial for treating generalized anxiety disorders. The company also develops SPL028 injectable deuterated DMT completed phase 1 clinical intramuscular and intravenous trial; SPL026 for MDD; and CYB005, a phenethylamine derivative, which in preclinical stage to treat central nervous system, as well as has a research pipeline of investigational psychedelic-based compounds. It has a strategic partnership agreement with Segal Trials to support PARADIGM, a multinational pivotal phase 3 program evaluating CYB003 for the adjunctive treatment of major depressive disorder. The company is headquartered in Toronto, Canada.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
